Ozempic, Wegovy, Zepbound Users Face Six Rebound Risks After Quitting
Dr. Frank Dumont of Virta Health says people who stop GLP-1 drugs such as Ozempic, Wegovy and Zepbound can see cravings return, weight regained and health markers reverse. He outlined six risks, citing two clinical trials.
Ozempic, Wegovy and Zepbound users face six potential rebound risks if they stop taking the drugs, according to Dr. Frank Dumont, an internal medicine physician and executive medical director at Virta Health in San Francisco. The warning matters because research shows many patients quit GLP-1 medications within a year.
Those risks range from rapid weight regain to the loss of cardiovascular protection, according to research Dumont discussed. GLP-1 drugs have reshaped weight management and diabetes control.
Why patients stop
Some patients stop because of medical concerns or side effects. Others prefer not to stay on long-term medication, Dumont said.
Common side effects include nausea, vomiting, constipation and diarrhea. "Those types of things can become troublesome enough that people actually have a hard time eating enough food to get good nourishment," he said.
Acute pancreatitis, a rarer side effect, would prompt immediate discontinuation. "We know that's fairly rare, but if the pancreas becomes involved, that is not a good thing," Dumont said. "It can be very serious. It can even be life-threatening."
Certain GLP-1 drugs carry a warning about thyroid tumors based on animal studies. The risk in humans is unknown. People with a personal or family history of medullary thyroid carcinoma, or of multiple endocrine neoplasia syndrome type 2, should not use them.
What happens after stopping
The first thing most patients notice is the return of intense cravings and a sharp spike in appetite, often called "food noise," Dumont said.
Many people treat GLP-1s like a short-term prescription, taking the drug to hit a target weight or blood sugar goal and then stopping. Major medical organizations, including the American Medical Association and the Obesity Medicine Association, classify obesity as a chronic condition that typically requires ongoing management.
"Unless you have significantly changed what you're doing in terms of the types of foods you're eating, it's likely you'll go back to the same foods you were eating before, and hunger and cravings will go up," Dumont said.
Weight regain is typical after quitting. In the STEP 1 trial extension, participants regained about two-thirds of the weight they had lost within a year of stopping semaglutide and lifestyle interventions.
In the SURMOUNT-4 trial of tirzepatide, patients switched to a placebo after 36 weeks regained more than half their lost weight over the following year. They did so even with diet and exercise counseling. "That's just so devastating for people who felt like they'd finally found a solution that would work," Dumont said.
Blood sugar, blood pressure and cholesterol tend to improve on a GLP-1, which helps people with prediabetes or diabetes. Those markers can reverse after the drug is stopped unless patients change their diet, Dumont said. Improvements in fatty liver disease may also fade.
Dumont advised patients to work with their physician on whether to stay on the medication.
